医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q1 FY18 Results on July 27, 2017

2017年07月14日 PM11:51
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the First Quarter ended June 30, 2017 on Thursday, July 27, 2017 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

Summary of Events

Event     Date and Time     Medium
Release of financial results     July 27th, after the Board Meeting    

Email, Media, Company website, Business Wire

Earnings Call     July 27th, 6.30 PM IST / 9:00 AM EDT     Hosted by the Company

(Details below)

Webcast of Earnings Call     July 27th , 6.30 PM IST / 9.00 AM EDT through July 31st    

URL available on Company’s website,

www.drreddys.com

Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

Press meet presentation     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

       

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through July 31, 2017. For play back dial in phone No: 022 3065 2322, and ID: 375#.

Conference Dial-In Numbers
Primary Number:   +91 22 3960 0616
     
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:   Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:   USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170714005339/en/

CONTACT

Dr. Reddy’s Laboratories
INVESTOR RELATIONS
SAUNAK SAVLA
Ph:
+91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER
Ph: +91-40- 49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film
  • U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
  • NINLARO® (ixazomib)维持治疗3期试验达到主要终点,显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义
  • 維持療法としてのニンラーロ(イキサゾミブ)を検討する第3相試験は主要評価項目を達成し、移植後の多発性骨髄腫患者で無増悪生存期間の統計的に有意な改善を実証
  • EUSA Pharma:NICE核准靶向癌症免疫治疗药物QARZIBA®▼ (dinutuximab beta)用于治疗高危神经母细胞瘤患儿